Immix Biopharma, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Operating income | -$30.0 | -$22.7 | -$16.1 | -$8.2 | -$1.4 |
| Net income | -$29.4 | -$21.6 | -$15.4 | -$8.2 | -$24.4 |
| Cash Flow Statement | |||||
| Free cash flow | -$24.7 | -$15.8 | -$11.4 | — | -$1.6 |
| Share repurchases | — | — | — | $0.1 | — |
Shares outstanding 71.5M · Free float 83.9%
Annual filing data through FY ended December 31, 2025; float as of October 6, 2026.
Immix Reports $13.9 Million Third-Quarter 2026 Net Loss, 89% Complete Response Rate in NEXICART-2